Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Recombinant tissue-type plasminogen activator,

Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999 282 2019-2026 [see comment]. [Pg.35]

Thrombolytic agents such as streptokinase, urokinase, and recombinant tissue-type plasminogen activator... [Pg.43]

Clinical trials One of the trials (ISIS-3) showed that streptokinase plus aspirin performed as well as recombinant tissue-type plasminogen activator (rt-PA) or complex formulations of streptokinase such as anistreplase (APSAC). The GUSTO trial showed a small advantage for the much more expensive t-PA over streptokinase, but with a significantly higher risk of hemorrhagic stroke. Nine clinical trials—each containing over 1000 patients with suspected acute myocardial infarction—... [Pg.774]

Zeymer U, von Essen R, Tebbe U, et al, Frequency of optimal anticoagulation for acute myocardial infarction after thrombolysis with front-loaded recombinant tissue-type plasminogen activator and conjunctive therapy with recombinant hirudin (HBW 023). ALKK Study Group. Am J Cardiol 1995 76 997-1001. [Pg.106]

Alteplase was the first commercially available recombinant tissue-type plasminogen activator (rt-PA) (25), It has a plasma half-life of less than five minutes and is metabolized by the liver, This agent was initially hailed as fibrin-specific unlike its precursors (urokinase and streptokinase). It was thought that this would result in a better safety profile, but this has not been born out in either the coronary or the peripheral experience, where actually there may be a higher bleeding risk as infusion time increases. Alteplase is currently indicated for use in the treatment of myocardial infarction, acute ischemic stroke, and pulmonary embolism. [Pg.576]

Fig. 4.14. Maps of the apparent diffusion coefficient (ADC) measured before and after embolic occlusion of the right middle cerebral artery in an animal without therapy (upper row) and in two animals with thrombolytic treatment initiated 1.5 h (middle row) and 4.5 h (lower row) after onset of ischemia. In the untreated animal, a decline of ADC was observed immediately after MCA occlusion that increased in size over time. Thrombolysis with recombinant tissue-type plasminogen activator (tPA) lead to the partial reversal of the ADC lesion over the first 5 h of therapy if started early. Late-onset thrombolysis at 4.5 h post occlusion did not reverse lesion growth, but was followed by a further lesion enlargement of the ischemic lesion. [Reproduced with permission from Hoehn et al. (2001)]... Fig. 4.14. Maps of the apparent diffusion coefficient (ADC) measured before and after embolic occlusion of the right middle cerebral artery in an animal without therapy (upper row) and in two animals with thrombolytic treatment initiated 1.5 h (middle row) and 4.5 h (lower row) after onset of ischemia. In the untreated animal, a decline of ADC was observed immediately after MCA occlusion that increased in size over time. Thrombolysis with recombinant tissue-type plasminogen activator (tPA) lead to the partial reversal of the ADC lesion over the first 5 h of therapy if started early. Late-onset thrombolysis at 4.5 h post occlusion did not reverse lesion growth, but was followed by a further lesion enlargement of the ischemic lesion. [Reproduced with permission from Hoehn et al. (2001)]...
Fong KL, Crysler CS, Mico BA, Boyle KE, Kopia GA, Kopaciewicz L, Lynn RE. Dose-dependent pharmacokinetics of recombinant tissue-type plasminogen activator in anesthetized dogs following intravenous infusion. Drug Metab Dis 1988 16 201-6. [Pg.290]

Hotchkiss A, Refino CJ, Leonard CK, O Connor JV, Crowley C, McCabe J,Tate K, Nakamura G, Powers D, Levinson A. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemostasis 1988 60 255-61. [Pg.291]

Bakhit C, Lewis D, Billings R, Malfroy B. Cellular catabolism of recombinant tissue-type plasminogen activator identification and characterization of a novel high affinity uptake system on rat hepatocytes. J Biol Chem 1987 262 8716-20. [Pg.291]

Gold HK, Coller BS, Yasuda T et al. (1988) Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet Gp Ilb/IIIa antibody in a canine preparation. Circulation 77 670-677 Gold HK, Fallon JT, Yasuda T et al. (1984) Coronary thrombolysis with recombinant human tissue-type plasminogen activator. Circulation 70 700-707... [Pg.287]

Shebuski RJ, Storer BL, Fujita T (1988) Effect of thromboxane synthetase inhibition on the thrombolytic action of tissue-type plasminogen activator in a rabbit model of peripheral arterial thrombosis. Thromb Res 52 381-392 Yasuda T, Gold HK, Fallon JT et al. (1988) Monoclonal antibody against the platelet glycoprotein (GP) Ilb/IIIa receptor prevents coronary artery reocclusion after reperfusion with recombinant tissue type plasminogen activator. J Clin Invest 81 1284-1291... [Pg.287]

Hergrueter CA, Handren J, Kersh R, May JW (1988) Human recombinant tissue-type plasminogen activator and its effect on microvascular thrombosis in the rabbit. Plast Reconstr Surg 81 418—424... [Pg.291]

Jang IK, Gold HK, Ziskind A A et al. (1989) Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 79 920-928... [Pg.291]

Saitoh S,SaitoT,Otake A, Owada T, Mitsugi M, HasfaimotoH.MaruyamaY Cilostazol, anovel cydic AMP pbos diodiesterase inhibitor, prevents reocdusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arteriosder Thromb 1993 13 563-570. [Pg.265]

Mickelson JK, Simpson PI, Cronin M, Homeister JW, Laywell E, Kitzen J, Lucchesi BR Antiplatelet antibody (7E3 ((ab IJ prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation (1990) 81 617-627. [Pg.524]

Gupta BK, Spinowitz BS, Charytan C, Wahl SJ. Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator. Am J Kidney Dis 1993 21(6) 659-62. [Pg.3406]

Becker RC, Caputo R, Ball S, Corrao JM, Baker S, Gore JM. Hemorrhagic potential of combined diltiazem and recombinant tissue-type plasminogen activator administration. Am Heart J 1993 126(1) 11-14. [Pg.3409]

Thrombosis is one of the most common and devastating diseases. Fibrinolytic enzymes are effectively in treating thrombosis. A variety of fibrinolytic enzymes, such as UK, streptokinase (SK), recombinant tissue-type plasminogen activator (rt-PA), staphylokinase (SAK) and recombinant prourokinase (pro-UK), have been studied as thrombolytic agents [67,68]. In general, these agents are administered via intravenous injection, and their limitations include fast clearance, lack of resistance to re-occlusion, bleeding complications and other adverse effects [67]. [Pg.839]

Grotta J. Combination therapy stroke trial Recombinant tissue-type plasminogen activator with/without lubeluzole. Cerebrovasc Dis. 2001 12 258-263... [Pg.21]

Modi N. Recombinant tissue-type plasminogen activator and factor VIII. In Crommelin DJA, Sindelar RD, eds. Pharmaceutical Biotechnology An Introduction for Pharmacists and Pharmaceutical Scientists. Amsterdam Harwood Academic Publishers, 1997 297-306. [Pg.273]

Verstraete M, Bernard R, Bory M, Brower RW, Collen D, deBono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Report from the European Cooperative Smdy Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985 1 842-847. [Pg.21]

Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction a rqx)rt from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998 31 1240-1245. [Pg.25]

Binbrek A, Rao N, Absher PM, Van de Werf E, Sobel BE. The relative rapidity of recanalization induced by recombinant tissue-type plasminogen activator (rt-PA) and TNK-tPA assessed with enzymatic methods. Coron Artery Dis 2000 11 429 35. [Pg.29]

Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombosis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989 14 1566-1569. [Pg.61]

See other pages where Recombinant tissue-type plasminogen activator, is mentioned: [Pg.43]    [Pg.37]    [Pg.38]    [Pg.294]    [Pg.255]    [Pg.252]    [Pg.121]    [Pg.247]    [Pg.399]    [Pg.844]    [Pg.38]    [Pg.60]   
See also in sourсe #XX -- [ Pg.420 ]



SEARCH



Active Tissues

Active type

Plasminogen

Plasminogen activation

Plasminogen activators

Recombinant tissue plasminogen

Recombinant tissue-plasminogen activator

Tissue plasminogen

Tissue plasminogen activator

Tissue typing

Tissue-type plasminogen activator

© 2024 chempedia.info